News

BenevolentAI announces $90 million investment from Temasek

New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform.

London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquartered investment company. Raine Advisors acted as exclusive financial advisors to BenevolentAI.  

BenevolentAI aims to improve the lives of patients suffering from diseases with no effective treatment. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy and lower the development time and costs of new treatments.  

The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development. BenevolentAI will continue to advance its growing pipeline of internal drug development programmes and collaborations with strategic partners across its key therapeutic areas. Most recently, BenevolentAI announced long-term collaborations with AstraZeneca and Novartis, which will generate meaningful revenues for BenevolentAI over a multi-year period.

Joanna Shields, CEO of BenevolentAI, said:

“We are pleased that Temasek has invested in us to support our mission to bring more effective medicines to the patients who need them. This year, we have demonstrated strong commercial and scientific progress and this funding will further scale our technology and support the development of our pipeline of potentially transformational medicines.”

The Benevolent Platform® is a leading computational and experimental drug discovery platform that enables scientists to uncover new ways to treat disease and personalise drugs for patients. It focuses on three key areas; target identification, molecular design and precision medicine, to better understand the underlying mechanisms of disease and to develop new treatments for the millions of patients who need them.



Notes to editors

More information, please contact
press@benevolent.ai

About BenevolentAI

BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to medicine. The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market.  The company has developed the ‘Benevolent Platform’, the world’s only end-to-end computational and experimental platform for drug discovery that’s spans data ingestion to clinical development

BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020